User contributions
Jump to navigation
Jump to search
- 19:38, 20 December 2023 diff hist +2 m Acute myeloid leukemia, FLT3-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:38, 20 December 2023 diff hist +2 m Post-transplant lymphoproliferative disorder Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:38, 20 December 2023 diff hist +2 m Colorectal cancer, KRAS-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:38, 20 December 2023 diff hist +2 m Waldenström macroglobulinemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:38, 20 December 2023 diff hist +2 m Antidepressants and other psychiatric medications in cancer care Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:38, 20 December 2023 diff hist +2 m Thyroid cancer, RET-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Dermatofibrosarcoma protuberans Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Ovarian cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Chronic myeloid leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Vascular sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Acquired hemophilia A Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only." current
- 19:37, 20 December 2023 diff hist +2 m Meningioma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Colon cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Malignant pleural mesothelioma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Hemophagocytic lymphohistiocytosis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Adrenocortical carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Transformed lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Vulvar cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Non-small cell lung cancer, squamous Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Sarcomatoid renal cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Inflammatory myofibroblastic tumor Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Thyroid cancer, medullary Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Hypereosinophilic syndrome Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Appendiceal tumor Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Clear cell renal cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Drug index Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Colorectal cancer, MSI-H or dMMR Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Thyroid cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Antiemesis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Pancreatic cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Craniopharyngioma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Essential thrombocythemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Prostate cancer, BRCA-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Carcinoma of unknown primary Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Rhabdomyosarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:37, 20 December 2023 diff hist +2 m Penile cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m NET of unknown primary Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Breast cancer, CNS metastases Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m T-cell prolymphocytic leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m HIV-associated lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m B-cell acute lymphoblastic leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Acute lymphoblastic leukemia, infant Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Gallbladder cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Anaplastic large cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Acute myeloid leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Bladder cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Esophageal adenocarcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Neuroendocrine carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Non-small cell lung cancer, nonsquamous Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Heparin-induced thrombocytopenia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Non-small cell lung cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Burkitt lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Bone sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Ewing sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Erdheim-Chester disease Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m ESMO guidelines Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m PJP Prophylaxis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Melanoma, BRAF-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Radiotherapy toxicity management Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only." current
- 19:36, 20 December 2023 diff hist +2 m Langerhans cell histiocytosis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:36, 20 December 2023 diff hist +2 m Glioblastoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Small bowel adenocarcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m T-cell acute lymphoblastic leukemia, pediatric Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Wilms tumor Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Sickle cell anemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Breast cancer, PIK3CA-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Peripheral T-cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Extranodal NK- and T-cell lymphoma, nasal type Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Soft tissue sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Anal cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Low-grade serous ovarian cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Colorectal cancer, BRAF-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Colorectal cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Diffuse large B-cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m CNS carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Follicular lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Pheochromocytoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Non-small cell lung cancer, HER2-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Esophageal squamous cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m NCCN guidelines Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Immune thrombocytopenia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Myelofibrosis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Ovarian cancer, HRD-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:35, 20 December 2023 diff hist +2 m Hepatocellular carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Venous thromboembolism Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Breast cancer, HER2-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Melanoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Nasopharyngeal carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Aplastic anemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Desmoid tumor Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Classical Hodgkin lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Urothelial carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Non-small cell lung cancer, ROS1-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m High-grade B-cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Systemic mastocytosis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Colorectal cancer, HER2-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Esophageal cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Kaposi sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Oropharyngeal cancer, HPV-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Antiphospholipid antibody syndrome Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Rectal cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Mantle cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Graft versus host disease Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Cholangiocarcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Breast cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Style guide Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m B-cell lymphoma of mucosa-associated lymphoid tissue Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:34, 20 December 2023 diff hist +2 m Renal cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Malignant solid neoplasm, MSI-H or dMMR Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Gastric cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m ASCO guidelines Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Pancreatic NET Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Merkel cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Non-Hodgkin lymphoma, pediatric Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Uveal melanoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Non-clear cell renal cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m PEComa Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Upper tract urothelial carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Leiomyosarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Primary mediastinal B-cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Non-small cell lung cancer, RET-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Acute myeloid leukemia, NPM1-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Periampullary adenocarcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Basics of Pain Management Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Hereditary hemorrhagic telangiectasia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Neutropenia & leukopenia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only." current
- 19:33, 20 December 2023 diff hist +2 m T-cell acute lymphoblastic leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Non-small cell lung cancer, KRAS-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Cancer-related fatigue Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Epithelioid sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:33, 20 December 2023 diff hist +2 m Colorectal cancer, RAS wild-type Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Warm autoimmune hemolytic anemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Tutorial Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Immune effector cells toxicity management Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Cutaneous squamous cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Polycythemia vera Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Non-small cell lung cancer, EGFR-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Liposarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Non-small cell lung cancer, MET-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Melanoma, KIT-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m NK- and T-cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Melanoma, NRAS-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m High-grade glioma, pediatric Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Chemotherapy-induced peripheral neuropathy Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only." current
- 19:32, 20 December 2023 diff hist +2 m Angiosarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Breast cancer, ER and HER2 co-expressing Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Endometrial cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Cervical cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Marginal zone lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m CNS melanoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Cutaneous T-cell lymphoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Thyroid cancer, differentiated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Antimicrobial prophylaxis Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Myelodysplastic syndrome Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Neuroendocrine tumor Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Malignant peritoneal mesothelioma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Rosai-Dorfman-Destombes disease Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:32, 20 December 2023 diff hist +2 m Papillary renal cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Medulloblastoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Breast cancer, BRCA-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Colon cancer, RAS wild-type Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Acute myeloid leukemia, IDH-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Castleman disease Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Giant-cell tumor of bone Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Thyroid cancer, BRAF-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Non-small cell lung cancer, CNS metastases Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Non-small cell lung cancer, BRAF-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Gastrointestinal stromal tumor Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Plasma cell leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Multiple myeloma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Myelodysplastic syndrome, IDH-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Inherited coagulopathy Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Osteosarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m B-cell acute lymphoblastic leukemia, Ph-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Testicular cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Breast cancer, triple negative Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Large granular lymphocytic leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Non-small cell lung cancer, ALK-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:31, 20 December 2023 diff hist +2 m Cutaneous basal cell carcinoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Malignant solid neoplasm, NTRK-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Head and neck cancer Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Chronic lymphocytic leukemia Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Alveolar soft part sarcoma Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Gastric cancer, HER2-positive Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +4 m Immunotherapy toxicity management Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Pancreatic cancer, BRCA-mutated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 19:30, 20 December 2023 diff hist +2 m Renal cell carcinoma, VHL-associated Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only."
- 16:06, 20 December 2023 diff hist -22 Cellular therapy conditioning regimens
- 16:06, 20 December 2023 diff hist 0 m Allogeneic HSCT Warner-admin moved page Allogeneic HSCT conditioning regimens to Allogeneic HSCT without leaving a redirect
- 16:05, 20 December 2023 diff hist 0 m Autologous HSCT Warner-admin moved page Autologous HSCT conditioning regimens to Autologous HSCT without leaving a redirect
- 16:04, 20 December 2023 diff hist -22 Main Page
- 18:14, 17 December 2023 diff hist +6 m Non-small cell lung cancer Text replacement - "b.[[" to "b. [["
- 01:58, 14 December 2023 diff hist +1 m Venous thromboembolism Text replacement - "| |}" to "|- |}"
- 01:58, 14 December 2023 diff hist +1 m Immunotherapy toxicity management Text replacement - "| |}" to "|- |}"
- 01:58, 14 December 2023 diff hist +1 m Prostate cancer tests Text replacement - "| |}" to "|- |}" current
- 01:58, 14 December 2023 diff hist +4 m Antiemesis Text replacement - "| |}" to "|- |}"
- 01:58, 14 December 2023 diff hist +1 m Allogeneic HSCT Text replacement - "| |}" to "|- |}"
- 17:57, 7 December 2023 diff hist +66 m High-grade B-cell lymphoma Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +22 m Primary mediastinal B-cell lymphoma Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +22 m Mantle cell lymphoma Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +88 m Diffuse large B-cell lymphoma Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +22 m Follicular lymphoma Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +22 m Tutorial Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +44 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:57, 7 December 2023 diff hist +66 m B-cell acute lymphoblastic leukemia Text replacement - "[[Autologous_HSCT#" to "[[Autologous_HSCT_conditioning_regimens#"
- 17:55, 7 December 2023 diff hist +22 m How I Treat Text replacement - "Autologous HSCT" to "Autologous HSCT conditioning regimens"
- 17:55, 7 December 2023 diff hist +22 m Main Page Text replacement - "Autologous HSCT" to "Autologous HSCT conditioning regimens"
- 01:37, 30 November 2023 diff hist -6 m B-cell acute lymphoblastic leukemia Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:37, 30 November 2023 diff hist -24 m CNS lymphoma Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:37, 30 November 2023 diff hist -6 m Acute myeloid leukemia, pediatric - historical Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:37, 30 November 2023 diff hist -12 m Acute myeloid leukemia Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:36, 30 November 2023 diff hist -12 m Acute myeloid leukemia, pediatric Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:36, 30 November 2023 diff hist -12 m Burkitt lymphoma Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:36, 30 November 2023 diff hist -6 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:36, 30 November 2023 diff hist -6 m Stem cell mobilization regimens Text replacement - "#Cyclophosphamide_.26_Etoposide_.28CYVE.29" to "#Cytarabine_.26_Etoposide_.28CYVE.29"
- 01:35, 30 November 2023 diff hist -72 Osteosarcoma →Cytarabine & Etoposide (CYVE) {{#subobject:7bb7cb|Regimen=1}}
- 01:34, 30 November 2023 diff hist -6 m Cellular therapy conditioning regimens Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 01:34, 30 November 2023 diff hist -12 m CNS lymphoma Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 01:34, 30 November 2023 diff hist -6 m Stem cell mobilization regimens Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 01:33, 30 November 2023 diff hist -6 m Acute myeloid leukemia, pediatric Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 01:33, 30 November 2023 diff hist -6 m Burkitt lymphoma Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 01:33, 30 November 2023 diff hist -6 m Acute myeloid leukemia Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 01:33, 30 November 2023 diff hist -6 m Osteosarcoma Text replacement - "Cyclophosphamide & Etoposide (CYVE)" to "Cytarabine & Etoposide (CYVE)"
- 19:59, 29 November 2023 diff hist +10 m Anaplastic large cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Hodgkin lymphoma, nodular lymphocyte-predominant Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Non-small cell lung cancer, RET-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Non-small cell lung cancer, MET-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Melanoma, BRAF-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m CNS melanoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Meningioma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Extranodal NK- and T-cell lymphoma, nasal type Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Giant-cell tumor of bone Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Oropharyngeal cancer, HPV-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:59, 29 November 2023 diff hist +10 m Burkitt lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m T-cell prolymphocytic leukemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m Anaplastic glioma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m Desmoid tumor Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m Rosai-Dorfman-Destombes disease Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m Ovarian cancer, HRD-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m Esophageal squamous cell carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:58, 29 November 2023 diff hist +10 m Non-clear cell renal cell carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Non-small cell lung cancer, HER2-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Myelodysplastic syndrome, IDH-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Rhabdomyosarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Ewing sarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Thyroid cancer, BRAF-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Acute promyelocytic leukemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Follicular lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:57, 29 November 2023 diff hist +10 m Post-transplant lymphoproliferative disorder Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:56, 29 November 2023 diff hist +10 m Primary mediastinal B-cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:56, 29 November 2023 diff hist +10 m Acute myeloid leukemia, IDH-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:56, 29 November 2023 diff hist +10 m Low-grade glioma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:55, 29 November 2023 diff hist +10 m Diffuse large B-cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:55, 29 November 2023 diff hist +10 m Langerhans cell histiocytosis Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:55, 29 November 2023 diff hist +10 m Upper tract urothelial carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:55, 29 November 2023 diff hist +10 m Breast cancer, BRCA-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:55, 29 November 2023 diff hist +10 m Cholangiocarcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:55, 29 November 2023 diff hist +10 m Non-small cell lung cancer, ROS1-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Smoldering multiple myeloma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Leiomyosarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Acute lymphoblastic leukemia, infant Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Neuroendocrine carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Epithelioid sarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Acute myeloid leukemia, NPM1-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Essential thrombocythemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Breast cancer, CNS metastases Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:54, 29 November 2023 diff hist +10 m Glioblastoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Esophageal adenocarcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m B-cell acute lymphoblastic leukemia, Ph-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Neuroendocrine tumor Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Breast cancer, ER-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Adrenocortical carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Sarcomatoid renal cell carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Non-small cell lung cancer, CNS metastases Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m HIV-associated lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Appendiceal tumor Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Thyroid cancer, medullary Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Breast cancer, triple negative Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:53, 29 November 2023 diff hist +10 m Angiosarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:52, 29 November 2023 diff hist +10 m Pheochromocytoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:52, 29 November 2023 diff hist +10 m T-cell acute lymphoblastic leukemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:52, 29 November 2023 diff hist +10 m Non-small cell lung cancer, KRAS-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Non-small cell lung cancer, EGFR-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Adult T-cell leukemia-lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Peripheral T-cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Prostate cancer, BRCA-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Colorectal cancer, RAS wild-type Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Colon cancer, RAS wild-type Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Melanoma, KIT-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Large granular lymphocytic leukemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:51, 29 November 2023 diff hist +10 m Marginal zone lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Clear cell renal cell carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Craniopharyngioma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Colorectal cancer, MSI-H or dMMR Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Colorectal cancer, KRAS-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m PEComa Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Papillary renal cell carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Erdheim-Chester disease Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m High-grade B-cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m T-cell acute lymphoblastic leukemia, pediatric Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Renal cell carcinoma, VHL-associated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m Alveolar soft part sarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m B-cell lymphoma of mucosa-associated lymphoid tissue Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:50, 29 November 2023 diff hist +10 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Tenosynovial giant cell tumor Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Colorectal cancer, HER2-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Polycythemia vera Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Chronic myelomonocytic leukemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Non-small cell lung cancer, nonsquamous Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Transformed lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:49, 29 November 2023 diff hist +10 m Osteosarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Low-grade serous ovarian cancer Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Castleman disease Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Melanoma, NRAS-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m NK- and T-cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Mantle cell lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Gallbladder cancer Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Gastric cancer, HER2-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Non-small cell lung cancer, squamous Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Thyroid cancer, differentiated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Nasopharyngeal carcinoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Breast cancer, PIK3CA-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m CNS lymphoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Myelofibrosis Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Breast cancer, ER and HER2 co-expressing Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:48, 29 November 2023 diff hist +10 m Liposarcoma Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:47, 29 November 2023 diff hist +10 m Non-small cell lung cancer, ALK-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:47, 29 November 2023 diff hist +10 m Pancreatic NET Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:47, 29 November 2023 diff hist +10 m Breast cancer, HER2-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:47, 29 November 2023 diff hist +10 m Acute myeloid leukemia, FLT3-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:46, 29 November 2023 diff hist +10 m Inflammatory myofibroblastic tumor Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:46, 29 November 2023 diff hist +10 m B-cell acute lymphoblastic leukemia Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:46, 29 November 2023 diff hist +10 m Pancreatic cancer, BRCA-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:46, 29 November 2023 diff hist +10 m Thyroid cancer, RET-positive Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:46, 29 November 2023 diff hist +10 m Non-small cell lung cancer, BRAF-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 19:46, 29 November 2023 diff hist +10 m Colorectal cancer, BRAF-mutated Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines"
- 13:43, 26 November 2023 diff hist +72 m Cervical cancer Text replacement - "#Brachytherapy" to "#Brachytherapy_protocol"
- 12:25, 26 November 2023 diff hist +12 m Multiple myeloma - null regimens Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:25, 26 November 2023 diff hist +24 m Multiple myeloma, relapsed-refractory Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:25, 26 November 2023 diff hist +312 m Multiple myeloma, induction Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +12 m Stem cell mobilization regimens Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +12 m Plasma cell leukemia Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +396 m Multiple myeloma, consolidation and maintenance Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +180 m Multiple myeloma - historical Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +12 m Light-chain (AL) amyloidosis - null regimens Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +24 m Complex multipart regimens Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:24, 26 November 2023 diff hist +36 m Light-chain (AL) amyloidosis Text replacement - "#Melphalan.2C" to "#Melphalan_monotherapy.2C"
- 12:23, 26 November 2023 diff hist +12 m Plasma cell leukemia Text replacement - "=Melphalan, then auto" to "=Melphalan monotherapy, then auto"
- 12:23, 26 November 2023 diff hist +12 m Multiple myeloma, consolidation and maintenance Text replacement - "=Melphalan, then auto" to "=Melphalan monotherapy, then auto"
- 12:23, 26 November 2023 diff hist +12 m Multiple myeloma, relapsed-refractory Text replacement - "=Melphalan, then auto" to "=Melphalan monotherapy, then auto"
- 12:23, 26 November 2023 diff hist +12 m Light-chain (AL) amyloidosis Text replacement - "=Melphalan, then auto" to "=Melphalan monotherapy, then auto"
- 12:23, 26 November 2023 diff hist +48 m Multiple myeloma - historical Text replacement - "=Melphalan, then auto" to "=Melphalan monotherapy, then auto"
- 16:12, 24 November 2023 diff hist +31 m Acute myeloid leukemia, pediatric Text replacement - "=CYVE" to "=Cyclophosphamide & Etoposide (CYVE)"
- 16:12, 24 November 2023 diff hist +31 m Cellular therapy conditioning regimens Text replacement - "=CYVE" to "=Cyclophosphamide & Etoposide (CYVE)"
- 16:12, 24 November 2023 diff hist +37 m B-cell acute lymphoblastic leukemia Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:11, 24 November 2023 diff hist +31 m Burkitt lymphoma Text replacement - "=CYVE" to "=Cyclophosphamide & Etoposide (CYVE)"
- 16:11, 24 November 2023 diff hist +37 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:11, 24 November 2023 diff hist +37 m Stem cell mobilization regimens Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:11, 24 November 2023 diff hist +74 m Burkitt lymphoma Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:11, 24 November 2023 diff hist +62 m CNS lymphoma Text replacement - "=CYVE" to "=Cyclophosphamide & Etoposide (CYVE)"
- 16:11, 24 November 2023 diff hist +74 m Acute myeloid leukemia, pediatric Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:11, 24 November 2023 diff hist +31 m Acute myeloid leukemia Text replacement - "=CYVE" to "=Cyclophosphamide & Etoposide (CYVE)"
- 16:10, 24 November 2023 diff hist +148 m CNS lymphoma Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:10, 24 November 2023 diff hist +74 m Acute myeloid leukemia Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:10, 24 November 2023 diff hist +37 m Acute myeloid leukemia, pediatric - historical Text replacement - "#CYVE" to "#Cyclophosphamide_.26_Etoposide_.28CYVE.29"
- 16:10, 24 November 2023 diff hist +31 m Stem cell mobilization regimens Text replacement - "=CYVE" to "=Cyclophosphamide & Etoposide (CYVE)"
- 16:09, 24 November 2023 diff hist +148 m Osteosarcoma →Cyclophosphamide & Etoposide {{#subobject:7bb7cb|Regimen=1}}
- 22:58, 22 November 2023 diff hist +173 MediaWiki:Sitenotice current
- 22:53, 22 November 2023 diff hist -96 Editing test page
- 22:53, 22 November 2023 diff hist +96 Editing test page
- 22:52, 22 November 2023 diff hist 0 N File:Kisspng-emoji-computer-icons-police-car-siren-5d13c924b69c66.632658731561577764748.jpg current
- 00:33, 22 November 2023 diff hist -3,600 MediaWiki:Sitenotice
- 14:33, 19 November 2023 diff hist -52 Main Page
- 23:17, 18 November 2023 diff hist 0 m Non-small cell lung cancer, squamous Text replacement - "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6075826/" to "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826/"
- 23:17, 18 November 2023 diff hist 0 m Non-small cell lung cancer, nonsquamous Text replacement - "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6075826/" to "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826/"
- 23:16, 18 November 2023 diff hist 0 m Non-small cell lung cancer, nonsquamous Text replacement - "https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5705936/" to "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936/"
- 23:16, 18 November 2023 diff hist 0 m Ewing sarcoma Text replacement - "https://doi.org/10.1200/JCO.2011.41.5703" to "https://doi.org/10.1200/jco.2011.41.5703"
- 23:14, 18 November 2023 diff hist 0 m Ewing sarcoma, pediatric Text replacement - "[[Ewing Sar" to "[[Ewing sar"
- 23:12, 18 November 2023 diff hist 0 m B-cell acute lymphoblastic leukemia - historical Text replacement - "Doxorubicin, L-Asparaginase" to "Doxorubicin, L-asparaginase"
- 23:12, 18 November 2023 diff hist 0 m B-cell acute lymphoblastic leukemia, pediatric - historical Text replacement - "Doxorubicin, L-Asparaginase" to "Doxorubicin, L-asparaginase"
- 23:12, 18 November 2023 diff hist 0 m T-cell acute lymphoblastic leukemia, pediatric Text replacement - "Doxorubicin, L-Asparaginase" to "Doxorubicin, L-asparaginase"
- 23:12, 18 November 2023 diff hist 0 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "Doxorubicin, L-Asparaginase" to "Doxorubicin, L-asparaginase"
- 23:05, 18 November 2023 diff hist 0 m Breast cancer, ER-positive - historical Text replacement - "Bilateral Oophorectomy" to "Bilateral oophorectomy"
- 15:31, 17 November 2023 diff hist 0 m Trimethoprim-Sulfamethoxazole (Bactrim DS) Text replacement - "Trimethoprim/Sulfamethoxazole (Bactrim DS)" to "Trimethoprim-Sulfamethoxazole (Bactrim DS)" current
- 14:57, 17 November 2023 diff hist -2 m Classical Hodgkin lymphoma Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)"
- 14:57, 17 November 2023 diff hist -14 m Cytarabine (Ara-C) Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)" current
- 14:57, 17 November 2023 diff hist -4 m Mantle cell lymphoma Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)"
- 14:57, 17 November 2023 diff hist -2 m Midostaurin (Rydapt) Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)" current
- 14:57, 17 November 2023 diff hist -2 m Venetoclax (Venclexta) Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)" current
- 14:57, 17 November 2023 diff hist -2 m Glasdegib (Daurismo) Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)" current
- 17:16, 7 November 2023 diff hist -20 m Drug index Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:16, 7 November 2023 diff hist -40 m Classical Hodgkin lymphoma - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:15, 7 November 2023 diff hist -20 m Bacillus Calmette-Guérin (BCG, TheraCys) Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine" current Tag: Redirect target changed
- 17:15, 7 November 2023 diff hist -40 m Colon cancer - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:15, 7 November 2023 diff hist -40 m Non-small cell lung cancer - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:15, 7 November 2023 diff hist -20 m Breast cancer - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:15, 7 November 2023 diff hist -20 m Diffuse large B-cell lymphoma - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:14, 7 November 2023 diff hist -60 m Melanoma - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:14, 7 November 2023 diff hist -20 m Valrubicin (Valstar) Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine" current
- 17:14, 7 November 2023 diff hist -20 m Nadofaragene firadenovec (Adstiladrin) Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine" current
- 17:14, 7 November 2023 diff hist -20 m Pembrolizumab (Keytruda) Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:14, 7 November 2023 diff hist -100 m BCG vaccine Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:14, 7 November 2023 diff hist -160 m Bladder cancer Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 17:14, 7 November 2023 diff hist -40 m B-cell acute lymphoblastic leukemia - historical Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine"
- 15:00, 6 November 2023 diff hist 0 m Pancreatic cancer Text replacement - ""part " to ""Part "
- 15:00, 6 November 2023 diff hist 0 m HIV-associated lymphoma Text replacement - ""part " to ""Part "
- 15:00, 6 November 2023 diff hist 0 m Medulloblastoma Text replacement - ""part " to ""Part "
- 14:59, 6 November 2023 diff hist 0 m Medulloblastoma - historical Text replacement - ""part " to ""Part "
- 14:59, 6 November 2023 diff hist 0 m B-cell acute lymphoblastic leukemia, Ph-positive Text replacement - ""part " to ""Part "
- 13:15, 5 November 2023 diff hist -299 Tutorial
- 13:15, 5 November 2023 diff hist -124 Thymoma
- 13:15, 5 November 2023 diff hist -204 Peripheral T-cell lymphoma
- 13:15, 5 November 2023 diff hist -242 Multiple myeloma
- 13:14, 5 November 2023 diff hist -168 Mantle cell lymphoma
- 13:14, 5 November 2023 diff hist -34 High-grade glioma, pediatric
- 13:14, 5 November 2023 diff hist -169 Follicular lymphoma
- 13:14, 5 November 2023 diff hist -175 Diffuse large B-cell lymphoma
- 13:13, 5 November 2023 diff hist -51 Cold agglutinin disease
- 13:13, 5 November 2023 diff hist -82 Classical Hodgkin lymphoma
- 13:13, 5 November 2023 diff hist -25 Chronic myeloid leukemia
- 13:13, 5 November 2023 diff hist -53 Chronic lymphocytic leukemia
- 13:12, 5 November 2023 diff hist -160 B-cell acute lymphoblastic leukemia
- 13:12, 5 November 2023 diff hist -141 Acute myeloid leukemia, FLT3-positive
- 13:12, 5 November 2023 diff hist -257 Acute myeloid leukemia
- 11:08, 5 November 2023 diff hist +195 m Chronic lymphocytic leukemia Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:08, 5 November 2023 diff hist +117 m Diffuse large B-cell lymphoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:08, 5 November 2023 diff hist +39 m Melanoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +39 m Primary mediastinal B-cell lymphoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +195 m Chronic lymphocytic leukemia - historical Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +39 m Follicular lymphoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +39 m Uveal melanoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +39 m Mantle cell lymphoma - historical Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +39 m Mantle cell lymphoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +78 m High-grade B-cell lymphoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:07, 5 November 2023 diff hist +39 m Follicular lymphoma - historical Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:06, 5 November 2023 diff hist +39 m B-cell acute lymphoblastic leukemia, pediatric Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:06, 5 November 2023 diff hist +78 m Transformed lymphoma Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:06, 5 November 2023 diff hist +78 m B-cell acute lymphoblastic leukemia Text replacement - "#FC|" to "#Cyclophosphamide_.26_Fludarabine_.28FC.29|"
- 11:06, 5 November 2023 diff hist +66 m Chronic lymphocytic leukemia - historical Text replacement - "==FC " to "==Cyclophosphamide & Fludarabine (FC) "
- 11:06, 5 November 2023 diff hist +33 m Allogeneic HSCT Text replacement - "==FC " to "==Cyclophosphamide & Fludarabine (FC) "
- 11:06, 5 November 2023 diff hist +33 m Follicular lymphoma - historical Text replacement - "==FC " to "==Cyclophosphamide & Fludarabine (FC) "
- 11:06, 5 November 2023 diff hist +33 m Mantle cell lymphoma - historical Text replacement - "==FC " to "==Cyclophosphamide & Fludarabine (FC) "
- 15:55, 30 October 2023 diff hist +4 m Nasopharyngeal carcinoma Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)"
- 15:55, 30 October 2023 diff hist +2 m Urothelial carcinoma Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)"
- 15:55, 30 October 2023 diff hist +35 N Toripalimab (Tuoyi) Warner-admin moved page Toripalimab (Tuoyi) to Toripalimab (Loqtorz): Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)" Tag: New redirect
- 15:55, 30 October 2023 diff hist 0 m Toripalimab (Loqtorzi) Warner-admin moved page Toripalimab (Tuoyi) to Toripalimab (Loqtorz): Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)"
- 15:55, 30 October 2023 diff hist +2 m Esophageal squamous cell carcinoma Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)"
- 15:55, 30 October 2023 diff hist +2 m Toripalimab (JS001) Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)" Tag: Redirect target changed
- 15:55, 30 October 2023 diff hist +2 m Drug index Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)"
- 15:55, 30 October 2023 diff hist +2 m Melanoma Text replacement - "Toripalimab (Tuoyi)" to "Toripalimab (Loqtorz)"
- 00:34, 30 October 2023 diff hist +74 Editorial Board
- 17:42, 29 October 2023 diff hist +3 m Editorial Board
- 20:54, 25 October 2023 diff hist +972 Editorial Board
- 13:04, 25 October 2023 diff hist 0 Editorial Board →Regional Associate Editors
- 13:02, 25 October 2023 diff hist +12 Editorial Board →Regional Associate Editors
- 13:00, 25 October 2023 diff hist -136 Editorial Board →Regional Associate Editors
- 12:58, 25 October 2023 diff hist +980 Editorial Board
- 12:56, 25 October 2023 diff hist 0 N File:Lythgoe.jpeg current
- 12:56, 25 October 2023 diff hist 0 N File:Kennedy.jpeg current
- 00:54, 25 October 2023 diff hist -4 m Acute myeloid leukemia Text replacement - "specific populations have been moved to dedicated pages" to "specific populations are located on dedicated pages"
- 12:11, 23 October 2023 diff hist +1 m CNS lymphoma Text replacement - "cells reinfused" to "cells re-infused"
- 12:11, 23 October 2023 diff hist +1 m Follicular lymphoma Text replacement - "cells reinfused" to "cells re-infused"
- 12:11, 23 October 2023 diff hist +5 m Diffuse large B-cell lymphoma Text replacement - "cells reinfused" to "cells re-infused"
- 12:11, 23 October 2023 diff hist +2 m Mantle cell lymphoma Text replacement - "cells reinfused" to "cells re-infused"
- 01:30, 21 October 2023 diff hist 0 Editorial Board
- 19:32, 19 October 2023 diff hist -1 Main Page
- 00:21, 18 October 2023 diff hist 0 m Emicizumab (Hemlibra) Text replacement - "/Factor Xa bi" to "-Factor Xa bi" current
- 00:21, 18 October 2023 diff hist 0 m Category:Anti-EpCAM bispecific T-cell engager antibodies Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current Tag: Redirect target changed
- 00:20, 18 October 2023 diff hist 0 m Catumaxomab (Removab) Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current
- 00:20, 18 October 2023 diff hist 0 m Category:Anti-CD20 bispecific T-cell engager antibodies Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current Tag: Redirect target changed
- 00:19, 18 October 2023 diff hist 0 m Category:Anti-EGFR-HGFR bispecific antibodies Warner-admin moved page Category:Anti-EGFR/HGFR bispecific antibodies to Category:Anti-EGFR-HGFR bispecific antibodies without leaving a redirect: Text replacement - "/HGFR bispecific" to "-HGFR bispecific"
- 00:19, 18 October 2023 diff hist 0 m Category:Anti-BCMA-CD3 bispecific antibodies Warner-admin moved page Category:Anti-BCMA/CD3 bispecific antibodies to Category:Anti-BCMA-CD3 bispecific antibodies without leaving a redirect: Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:19, 18 October 2023 diff hist 0 m Category:Anti-BCMA bispecific T-cell engager antibodies Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current Tag: Redirect target changed
- 00:18, 18 October 2023 diff hist 0 m Category:Anti-CD33-CD3 bispecific antibodies Warner-admin moved page Category:Anti-CD33/CD3 bispecific antibodies to Category:Anti-CD33-CD3 bispecific antibodies without leaving a redirect: Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:18, 18 October 2023 diff hist 0 m Category:Anti-Factor IXa-Factor Xa bispecific antibodies Warner-admin moved page Category:Anti-Factor IXa/Factor Xa bispecific antibodies to Category:Anti-Factor IXa-Factor Xa bispecific antibodies without leaving a redirect: Text replacement - "/Factor Xa bi" to "-Factor Xa bi"
- 00:18, 18 October 2023 diff hist 0 m Blinatumomab (Blincyto) Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:17, 18 October 2023 diff hist 0 m Category:Anti-EpCAM-CD3 bispecific antibodies Warner-admin moved page Category:Anti-EpCAM/CD3 bispecific antibodies to Category:Anti-EpCAM-CD3 bispecific antibodies without leaving a redirect: Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:17, 18 October 2023 diff hist 0 m Category:Anti-CD33 bispecific T-cell engager antibodies Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current Tag: Redirect target changed
- 00:17, 18 October 2023 diff hist 0 m Category:Anti-GPRC5D bispecific T-cell engager antibodies Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current Tag: Redirect target changed
- 00:16, 18 October 2023 diff hist 0 m Category:Anti-CD19 bispecific T-cell engager antibodies Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current Tag: Redirect target changed
- 00:16, 18 October 2023 diff hist 0 m Mosunetuzumab (Lunsumio) Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current
- 00:15, 18 October 2023 diff hist 0 m Amivantamab (Rybrevant) Text replacement - "/HGFR bispecific" to "-HGFR bispecific"
- 00:15, 18 October 2023 diff hist 0 m Teclistamab (Tecvayli) Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:15, 18 October 2023 diff hist 0 m Category:Anti-CD20-CD3 bispecific antibodies Warner-admin moved page Category:Anti-CD20/CD3 bispecific antibodies to Category:Anti-CD20-CD3 bispecific antibodies without leaving a redirect: Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:15, 18 October 2023 diff hist 0 m Elranatamab (Elrexfio) Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:15, 18 October 2023 diff hist 0 m Category:Anti-CD19-CD3 bispecific antibodies Warner-admin moved page Category:Anti-CD19/CD3 bispecific antibodies to Category:Anti-CD19-CD3 bispecific antibodies without leaving a redirect: Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:15, 18 October 2023 diff hist 0 m Melphalan for Injection-Hepatic Delivery System (Hepzato Kit) Warner-admin moved page Melphalan for Injection/Hepatic Delivery System (Hepzato Kit) to Melphalan for Injection-Hepatic Delivery System (Hepzato Kit) without leaving a redirect: Breaking special character current
- 00:14, 18 October 2023 diff hist 0 m Eluvixtamab (AMG-330) Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current
- 00:14, 18 October 2023 diff hist 0 m Epcoritamab (Epkinly) Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current
- 00:13, 18 October 2023 diff hist 0 m Category:Anti-GPRC5D-CD3 bispecific antibodies Warner-admin moved page Category:Anti-GPRC5D/CD3 bispecific antibodies to Category:Anti-GPRC5D-CD3 bispecific antibodies without leaving a redirect: Text replacement - "/CD3 bispecific" to "-CD3 bispecific"
- 00:13, 18 October 2023 diff hist 0 m Glofitamab (Columvi) Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current
- 00:13, 18 October 2023 diff hist 0 m Talquetamab (Talvey) Text replacement - "/CD3 bispecific" to "-CD3 bispecific" current
- 23:07, 17 October 2023 diff hist -11 m Response to treatment Text replacement - "===Older===" to "" current
- 23:07, 17 October 2023 diff hist -11 m Merkel cell carcinoma Text replacement - "===Older===" to ""
- 23:07, 17 October 2023 diff hist -11 m Hereditary hemorrhagic telangiectasia Text replacement - "===Older===" to ""
- 23:07, 17 October 2023 diff hist -11 m Gastric cancer Text replacement - "===Older===" to ""
- 23:07, 17 October 2023 diff hist -11 m Gallbladder cancer Text replacement - "===Older===" to ""